1-(3′-[125I]iodophenyl)-3-methy-2-pyrazolin-5-one: Preparation, solution stability, and biodistribution in normal mice

Chemical and Pharmaceutical Bulletin

Volumn 58, Issue 8, 2010, Pages 1020-1025

  Sano, Yuuhei ^a   Motomura, Tomokazu ^a   Yamamoto, Fumihiko ^a   Fukuda, Miki ^a   Mukai, Takahiro ^a   Maeda, Minoru ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Biodistribution; Edaravone; Labeling; Mouse; Radioiodine; Stability

Indexed keywords

IODOEDARAVONE I 125; NORPHENAZONE; UNCLASSIFIED DRUG; 1 (3' IODOPHENYL) 3 METHY 2 PYRAZOLIN 5 ONE; 1-(3'-IODOPHENYL)-3-METHY-2-PYRAZOLIN-5-ONE; ANTIOXIDANT; DRUG DERIVATIVE; PHENAZONE; PHENYLMETHYLPYRAZOLONE; PYRAZOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PARTITION COEFFICIENT; RADIOCHEMISTRY; RADIOISOTOPE DISTRIBUTION; TISSUE DISTRIBUTION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG STABILITY; INSTITUTE FOR CANCER RESEARCH MOUSE; SOLUBILITY; SYNTHESIS;

ANIMALS; ANTIOXIDANTS; ANTIPYRINE; DRUG STABILITY; MALE; MICE; MICE, INBRED ICR; MOLECULAR STRUCTURE; PYRAZOLONES; SOLUBILITY; TISSUE DISTRIBUTION;

EID: 77955382296     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.58.1020     Document Type: Article

References (36)

1. Nemoto S., Takeda K., Yu Z.-X., Ferrans V. J., Finkel T., Mol. Cell. Biol., 20, 7311-7318 (2000).
2. Valko M., Leibfritz D., Moncol J., Cronin M. T. D., Mazur M., Telser J., Int. J. Biochem. Cell Biol., 39, 44-84 (2007).
3. Gutierrez J., Ballinger S. W., Darley-Usmarr V. M., Landar A., Cir. Res., 99, 924-932 (2006).
4. Dreher D., Junod A. F., Eur. J. Cancer, 32A, 30-38 (1996).
5. Zweier J. L., Talukder M. A. H., Cardiovasc. Res., 70, 181-190 (2006).
6. Bartosz G., Clinica Chimica Acta, 368, 53-76 (2006).
7. Wardman P., Free Radic. Biol. Med., 43, 995-1022 (2007).
8. Halliwell A., Whiteman M., Br. J. Pharmacol., 142, 231-255 (2004).
9. Tarpey M. M., Wink D. A., Grisham M. B., Am. J. Physiol. Regul. Integr. Comp. Physiol., 286, R431-R444 (2004).
10. Eckelman W. C., Rebaand R. C., Kelloff G. L., Drug Discov. Today, 13, 748-759 (2008).
11. Wada K., Fujibayashi Y., Tajima N., Yokoyama A., Nucl. Med. Biol., 21, 901-904 (1994).
12. Fujibayashi Y., Tajima N., Wada K., Waki A., Sakahara H., Konishi K., Yokoyama A., Nucl. Med. Biol., 24, 399-403 (1997).
13. Bormans G., Kilbourn M. R., J. Labelled Compd. Radiopharm., 36, 103-110 (1995).
14. Gilissen C., Bormans G., de Groot T., Verbruggen A., J. Labelled Compd. Radiopharm., 40, 491-502 (1998).
15. The Edaravone Acute Brain Infarction Study Group, Cerebrovasc. Dis., 15, 222-229 (2003).
16. Watanabe T., Yuki S., Egawa M., Nishi H., J. Pharmacol. Exp. Ther., 268, 1597-1604 (1994).
17. Kawai H., Nakai H., Suga M., Yuki S., Watanabe T., Saito K., J. Pharmcaol. Exp. Ther., 281, 921-927 (1997).
18. Wu T.-W., Zeng L.-H., Wu J., Fung K.-P., Life Sci., 71, 2249-2255 (2002).
19. Tajima S., Soda M., Bando M., Enomoto M, Yamasawa H., Ohno S., Takada T., Suzuki E., Gejyo F., Sugiyama Y., Respirology, 13, 646-653 (2008).
20. Watanabe Kazut., Watanabe Kazuh., Kuwahara T., Yamamoto Y., J. Jpn. Oil Chem. Soc., 46, 797-808 (1997).
21. Watanabe Kazut., Watanabe Kazuh., Hayase T., Jpn. Pharmacol. Ther., 25, 1699-1707 (1997).
22. Komatsu T., Nakai H., Takamatsu Y., Morinaka Y., Watanabe K., Shimoda A., Iida S., Drug Metab. Pharmacokin., 11, 451-462 (1996).
23. Komatsu T., Nakai H., Masaki K., Obata R., Nakai K., Iida S., Drug Metab. Pharmacokin., 11, 463-480 (1996).
24. Garg P. K., Slade S. K., Harrison C. L., Zalutsky M. R., Nucl. Med. Biol., 16, 669-673 (1989).
25. Hunsberger I. M., Shaw E. R., Fugger J., Ketcham R., Lednicer D., J. Org. Chem., 21, 394-399 (1956).
26. Jansen M., Dannhardt G., Eur. J. Med. Chem., 38, 855-865 (2003).
27. Watanabe K., Morinaka Y., Iseki K., Watanabe T., Yuki S., Nishi H., Redox Rep., 8, 151-155 (2003).
28. Chegaev K., Cena C., Giorgis M., Rolando B., Tosco P., Bertinaria M., Fruttero R., Carrupt P.-A., Gasco A., J. Med. Chem., 52, 574-578 (2009).
29. Yamamoto Y., Kuwahara T., Watanabe K., Watanabe T., Redox Rep., 2, 333-338 (1996).
30. Ono S., Okazaki K., Sakurai M., Inoue Y., J. Phys. Chem. A, 101, 3769-3775 (1997).
31. Blois M. S., Nature (London), 181, 1199-1200 (1958).
32. Nakagawa H., Ohyama R., Kimata A., Suzuki T., Miyata N., Bioorg. Med. Chem. Lett., 16, 5935-5942 (2006).
33. Kimata A., Nakagawa H., Ohyama R., Fukuchi T., Ohta S., Suzuki T., Miyata, N., J. Med. Chem., 50, 5053-5056 (2007).
34. Coenen H. H., Mertens J., Maziere B., "Radioiodination Reactions for Radiopharmaceuticals," Springer, The Netherland, 2006.
35. Ali H., van Lier J. E., Synthesis, 1996, 423-445 (1996).
36. Komatsu T., Masaki K., Nakai H., Jpn. Pharmacol. Ther., 25 (Suppl. 7), S1773-S1783 (1997).